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Background: Patients with type 2 diabetes (T2D) are at increased cardiovascular (CV) risk 
compared to subjects without diabetes, with some data estimating that CV disease (CVD) risk 
is doubled in these individuals. Additionally, CVD remains the leading cause of death in patients 
with T2D, so it is paramount to determine the relationship between these two diseases.
Purpose: Older diabetes treatments have limited CV safety data. In 2008, the US Food and Drug 
Administration published guidance for manufacturers on antihyperglycemic agents, requiring 
studies to ensure CV safety of new therapies. Since then, manufacturers of many newer agents 
have conducted and published results from CV outcomes trials (CVOTs), with more trials due 
to publish soon. This review discusses the relationship between CVD and T2D and explores 
findings from the latest CVOTs of glucose-lowering agents to guide nurse practitioners in their 
prescribing patterns for patients with T2D.
Conclusion: Patients with T2D are at high risk of CVD, so CV risk should be carefully con-
sidered when managing these patients, and CV risks and benefits of antidiabetic drugs should 
be included in prescribing decisions.
Keywords: cardiovascular disease, chronic disease management, type 2 diabetes mellitus, 
nurse practitioners
Overview of the relationship between 
cardiovascular risk and type 2 diabetes
Prior to the advent of insulin therapy, limited tools were available to prevent the progres-
sion of diabetes. As patient survival increased with insulin use, cardiovascular (CV) dis-
ease (CVD) management emerged as a key priority in improving patient lives.1 Patients 
with type 2 diabetes (T2D) are still at increased CV risk compared to their peers without 
diabetes, with some data suggesting that they are at double the risk of CVD compared 
to their healthy counterparts.1–3 CVD also remains the leading cause of death in T2D.4,5
A scientific statement from the American Heart Association and the American 
Diabetes Association (ADA) explains that for every 18 mg/dL (1 mmol/L) increase 
in fasting plasma glucose, the risk of future CV events or death increases by 17%.2 A 
rise of 1% (11 mmol/mol) in HbA
1c
 results in an 18% increase in risk of CV events.2 
Furthermore, an analysis of eleven large, integrated health care organizations in the 
United States found an increased CV risk if HbA
1c
 was ≥9% (75 mmol/mol).6 The 
European Prospective Investigation of Cancer and Nutrition (EPIC)-Norfolk study 
found that an increase of 1% in HbA
1c
 is associated with a 28% increase in risk of 
all-cause death in men, independent of age, blood pressure, serum cholesterol, body 
mass index, and cigarette smoking (P<0.002).7
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Data from the UKPDS trial in patients with T2D without 
CVD demonstrated a reduction of at least 12% in the risk 
of CV complications with every 1% decrease in HbA
1c
,8 as 
well as a reduction in the risk of myocardial infarction (MI) 
with intensive vs standard therapy after 10-year observation.9 
According to the ADA/European Association for the Study 
of Diabetes (EASD) Position Statement 2015, the impact of 
glucose control on CV complications remained to be fully 
elucidated at that time; a benefit may only emerge after 
many years of improved glycemic control.10 Consequently, 
the ADA and EASD have recently released a joint consensus 
report to aid the decision-making process when prescribing 
antidiabetic therapies, with emphasis being placed on the 
management of CV risk factors.11
This review will discuss the relationship between CVD 
and T2D and examine the findings from the latest CV out-
comes trials (CVOTs) of glucose-lowering agents.
Cardiovascular outcomes trials in type 2 
diabetes
Historically, new therapies for T2D required evidence for 
improving glycemic control from Phase II and III trials. 
However, in 2008, after the controversial results from a 
meta-analysis of rosiglitazone trials,12 the US Food and 
Drug Administration published “Guidance for industry”, 
stating that manufacturers of all new antidiabetic therapies 
must also demonstrate that the therapy will not result in an 
increased risk for CVD.13 Since this guidance was produced, 
a number of CVOTs have been conducted, to ensure that 
antidiabetic agents do not increase the risk of CV events. In 
CVOT design, a glucose-lowering drug is added to standard 
of care (SoC) treatments in patients at high risk of CV events 
(either patients with advanced diabetes, elderly patients, or 
those with renal impairment), and compared with SoC alone 
or added to an active comparator. The majority of CVOTs 
use a composite primary outcome known as a 3-point 
major adverse cardiovascular event (MACE), comprising 
CV death, nonfatal MI, and nonfatal stroke. Some also 
include hospitalization for heart failure (HF) and/or other 
endpoints.13 According to the guidance, CVOTs compar-
ing an antihyperglycemic agent with a comparator must 
demonstrate that the upper bound of a two-sided 95% CI 
is <1.8.13 Recently, results from these CVOTs have demon-
strated that some newer glucose-lowering therapies appear 
not only to have no detrimental impact on CV safety but 
additionally have beneficial effects on CVD beyond simple 
glucose control.14–16
Review of the cardiovascular safety 
profile of medications for type 2 diabetes
All manufacturers of dipeptidyl peptidase 4 inhibitors (DPP-
4is), sodium–glucose cotransporter-2 inhibitors (SGLT-2is), 
and glucagon-like peptide-1 receptor agonists (GLP-1RAs) 
have initiated CVOTs, many of which are complete, and there 
are a number of other drugs with demonstrable CV safety 
(Table 1). Many older drugs do not have published CVOTs, but 
some have established CV outcomes from other trials (Table 1).
Metformin, sulfonylureas, thiazolidinediones, 
meglitinides, and alpha-glucosidase inhibitors
Metformin remains the mainstay of first-line therapy in 
the treatment of T2D17 owing to its efficacy in lowering 
glucose, neutral effect on weight, minimal hypoglycemia, 
and low cost. Metformin has also been shown to reduce 
the risk of CV outcomes, including MI, HF, and stroke.18 
Sulfonylureas (SUs) appear to have mixed effects on CV 
endpoints. A meta-analysis of randomized controlled trials 
with SUs demonstrated no significant effects on MACE or 
MI independently, but an association with an increased risk 
of stroke and CV death was observed.19 The thiazolidinedione 
(TZD) rosiglitazone is associated with an increased risk of 
MI and CV mortality.12 Despite later data from the RECORD 
trial showing no increased risk in overall CV morbidity 
and mortality20 (although it did show an increase in HF), 
it is generally well accepted that the initial results from the 
meta-analysis are more reliable than RECORD, as this trial 
was unblinded.21,22 Conversely, patients treated with another 
TZD, pioglitazone, experienced a reduction in the progres-
sion of atherosclerosis, significantly reduced plasma lipid 
levels compared with rosiglitazone, and decreased apoptosis 
induced by ischemic injury, suggesting that the CV effects of 
TZDs are not a class effect.23 The CV safety of meglitinides 
is yet to be fully elucidated,24 although the NAVIGATOR 
study demonstrated similar rates in CV outcomes in patients 
treated with nateglinide compared with those treated with 
placebo.25 Data are also lacking on the CV safety of alpha-
glucosidase inhibitors, although the Acarbose Cardiovascular 
Evaluation (ACE) trial demonstrated no reduction in MACE 
in Chinese patients with impaired glucose tolerance treated 
with acarbose.26
The clinical implications of CvOT data for older 
antidiabetic therapies
Although metformin has the longest history of CV safety in 
antidiabetic therapies, there are no modern CVOTs to assess 
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benefits and safety of metformin on a background of current 
SoC for glucose control and other CV risk factors. Treatment 
with SUs is associated with weight gain, which remains 
a concern in patients with T2D. Moreover, an increased 
possibility of CV death and stroke means that prescribers 
should probably avoid these agents in patients at high risk 
for these events. Furthermore, rosiglitazone has had mixed 
CV results,12,20 indicating its use in patients at high risk for 
CV events needs to be considered carefully.
Newer therapies for T2D: dipeptidyl peptidase-4 
inhibitors (DPP-4is), sodium-glucose cotransporter-2 
inhibitors (SGLT-2is), glucagon-like peptide-1 
receptor agonists (GLP-1RAs), and second-
generation insulin analogs
A comprehensive meta-analysis evaluating data from 170 ran-
domized controlled trials comparing the CV effects of novel 
antidiabetic medications (including DPP-4is, GLP-1RAs, 
and SGLT-2is) with those of traditional classes of drugs 
(including insulin, metformin, SU, and TZD) determined 
that, in general, newer antidiabetic agents show favorable 
CV safety, yet discrepancies exist between individual and 
class comparisons.27
To date, all CVOTs of DPP-4is have reported 
 noninferiority in terms of CV safety with the composite 
MACE endpoint when compared with placebo, both on a 
background of SoC, thus suggesting no harm.28–30 Results 
from a recently published meta-analysis also confirmed a 
lack of CV benefit and inferred that DPP-4is are inferior to 
SGLT-2is and GLP-1RAs in preventing CV-related death.31 
The CAROLINA trial is yet to publish results for the CV 
safety of linagliptin (NCT01243424, Clinicaltrials.gov). 
However, preliminary findings from the CARMELINA 
trial suggest that treatment with linagliptin has no impact 
on CV and HF events.32
Notably, some negative individual CV outcomes have 
been revealed with specific DPP-4is. Saxagliptin has been 
associated with an increased risk for hospitalization for HF.33 
While alogliptin was not associated with increased risk of 
certain HF outcomes (such as hospital admission for HF) 
compared with placebo, hospital admissions for HF occurred 
significantly more often in patients without prior history of 
HF treated with alogliptin compared with placebo.34
Other DPP-4is have not been associated with an 
increased risk of HF. Both linagliptin and sitagliptin do not 
appear to increase the risk of HF in patients with diabetes.35 
As these results are conflicting with those from saxagliptin 
and alogliptin, the HF concerns may not be a class effect, 
and currently, no mechanism for the association between 
DPP-4is and HF has been identified.35 It should be noted 
that the trial designs and patient population of these trials 
are not directly comparable, and therefore these safety dif-
ferences may be attributable to these other factors rather 
than to the drugs.
Findings from two recent meta-analyses of data on 
SGLT-2is suggest favorable effects against CV outcomes 
and death.36,37 These reflect that the CVOT data for SGLT-2is 
empagliflozin and canagliflozin have demonstrated superi-
ority of the trial drug in MACE outcomes when compared 
with SoC, suggesting a cardioprotective effect of these 
agents.14,15 Data from the EMPA-REG OUTCOME trial with 
empagliflozin led to an update in the label, and the therapy 
is now indicated to reduce the risk of CV death in patients 
with T2D and established CVD.38 This decision has since 
been validated by the ADA and EASD.11,39,40 The DECLARE-
TIMI 58 Phase III CVOT with dapagliflozin demonstrated 
noninferiority, but not superiority, for MACE.41 When the 
components of this composite endpoint were analyzed, it was 
shown that dapagliflozin significantly reduced the number of 
hospitalizations for HF.41 It seems unlikely therefore that the 
CV benefits associated with empagliflozin and canagliflozin 
are a class effect, but perhaps there is a class effect for HF. 
It is also unknown if empagliflozin, canagliflozin, or other 
SGLT-2is will have similar effects in patients with T2D but 
at low CV risk.40
Data from further CVOTs with ertugliflozin and sota-
gliflozin may help to elucidate if any SGLT-2i class effect 
exists (NCT01986881 and NCT03521934, respectively, 
Clinicaltrials.gov). The current ongoing VERTIS CV study 
assesses ertugliflozin in patients with T2D and established 
vascular disease, and the SOLOIST-WHF trial assesses 
sotagliflozin in patients with T2D with worsening HF. It 
will still be some time before the long-term safety and real-
world impact of SGLT-2is in patients with T2D with HF/
CVD become clear.
Meta-analyses of CVOT data on GLP-1RAs suggest car-
dioprotective effects in patients with high CV risk.42,43 A CV 
benefit was demonstrated in both the LEADER trial and the 
HARMONY Outcomes trial for the GLP-1RAs liraglutide 
and albiglutide, respectively, when compared with SoC.16,44 
Also, even though testing for superiority of the primary com-
posite endpoint was not prespecfied in SUSTAIN 6, a post hoc 
analysis of its data suggests that the once-weekly subcutane-
ous GLP-1RA, semaglutide, may also offer a CV benefit.45 
In the LEADER trial, significantly fewer patients treated 
with liraglutide experienced MACE, compared with those 
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treated with placebo, a statistically superior result.16 This led 
to an update in the label, and liraglutide is now indicated to 
reduce the risk of MACE in patients with T2D and established 
CVD,46 which is also reflected in the new consensus report 
from the ADA/EASD.11 The SUSTAIN 6 trial demonstrated 
noninferiority of subcutaneous semaglutide to placebo for 
MACE, and a post hoc analysis also showed superior CV 
benefit for patients treated with semaglutide compared with 
those treated with placebo. Testing for superiority was not 
prespecified or adjusted for multiplicity.45 In the HARMONY 
Outcomes trial, albiglutide therapy was found to be superior 
to placebo with respect to MACE and resulted in a significant 
reduction in MIs (it is important to note that albiglutide is no 
longer commercially available).44
In comparison, lixisenatide and once-weekly exenatide 
have only demonstrated noninferiority compared with pla-
cebo.47,48 Study investigators in the EXSCEL trial with once-
weekly exenatide suggested that the disproportionate use of 
diabetes therapies known to reduce CV risk in the placebo 
group, such as SGLT-2is and other GLP-1RAs, may have pref-
erentially resulted in lower event rates in the placebo arm.48
Whether there is a GLP-1RA class effect in CV safety 
remains to be determined, but appears unlikely given the 
results obtained thus far in CVOTs. As yet, the mechanism 
underlying the emerging cardioprotective effect of GLP-
1RAs has not been identified and it is unknown whether this 
effect occurs via GLP-1, its receptor, or other pathways.49 The 
mixed results seen in CVOTs of GLP-1RAs may be attributed 
to varying molecular structures, as human analogs appear to 
perform better than the exendins, which are larger than, and 
molecularly different to, the human analogs. Further clarity 
will be available after the results from REWIND with dula-
glutide and PIONEER 6 with oral semaglutide are published 
in full (NCT01394952 and NCT02692716, respectively; 
Clinicaltrials.gov).
Only two basal insulins have been investigated in CVOTs. 
Trials with insulin glargine (U100 Lantus) demonstrated no 
significant difference in MACE compared with SoC in the 
ORIGIN trial,50 and the DEVOTE trial revealed noninferi-
ority of insulin degludec compared with insulin glargine in 
MACE.51
The clinical implications of CvOT data for newer 
antidiabetic therapies
Newer agents DPP-4is, GLP-1RAs, and SGLT-2is have 
the most data on CV effects. As DPP-4is do not appear 
to improve CV outcomes compared with controls, it is 
unlikely that they will be used to reduce CV benefits. 
Although, real-world data have demonstrated that the 
 benefits seen with empagliflozin in CVOTs are applicable 
to a broad population of patients with T2D in clinical 
 practice,52 it is uncertain how trial outcomes for other 
SGLT-2is will translate into the real-world setting. Addi-
tionally, safety evidence is lacking in specific populations, 
such as the very elderly population.
The GLP-1RAs liraglutide and semaglutide have 
also demonstrated a benefit in CV outcomes,16,45 which 
supports their use in patients at high risk of CV events. 
This fact has been highlighted by the ADA/EASD, who 
have given preference to the use of liraglutide, based on 
the LEADER trial, and empagliflozin, based on EMPA-
REG OUTCOME, in this patient population.11 Further 
information on the long-term effects of these agents and 
the mechanisms behind their functions will become avail-
able with the arrival of results from ongoing and future 
CVOTs with GLP-1RA and SGLT-2is. Going forward, 
some investigators are exploring the potential to broaden 
the use of newer antidiabetic therapies beyond that of T2D. 
The Phase III EMPEROR-Preserved and EMPEROR-
Reduced trials investigating empagliflozin in patients 
with chronic HF are presently ongoing (NCT03057951 
and NCT03057977, respectively; Clinicaltrials.gov) and, 
once published, will offer insight into the potential non-
diabetic use of these agents.
Both insulin glargine and insulin degludec are associated 
with no increased risk of CV events compared with SoC.50,51 
However, weight gain and hypoglycemia remain a concern 
with insulin,53 and therefore other injectable therapies may 
be more appropriate prior to initiating insulin regimens. 
This is reflected in the ADA/EASD 2018 consensus report, 
wherein GLP-1RAs are generally recommended as the first 
injectable therapy.11
CV events are not the only adverse events collected 
for analysis during CVOTs. On occasion, some of these 
other events may indicate an unexpected safety signal. For 
example, in CANVAS, it was determined that there was a 
twofold increase in the number of lower-extremity amputa-
tions reported with canagliflozin therapy.15 This resulted in 
a boxed warning about the risk of lower limb amputation on 
the prescribing information leaflet.54 Also, SGLT-2is increase 
the risk of genital infections.14,15,38,54 These other adverse 
events indicate the need for nurse practitioners to be aware 
of all data reported from such studies and to discuss carefully 
risks and benefits with patients. Further clinical evaluation 
and documentation of vascular status and sensation with 
thorough foot exams are prudent as well.
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Conclusion
CV benefits are typically observed alongside glycemic effi-
cacy even with older treatments, such as metformin, although 
no CVOTs for these treatments have been completed. Having 
effective glucose-lowering agents that also demonstrate mul-
tifaceted benefits such as CVD risk reduction has profound 
implications for the development of new agents that will, by 
necessity, have to be compared with strategies of care that 
include SGLT-2is and GLP-1RAs. Nurse practitioners have 
data to support making informed decisions based on the CV 
effects of different therapies and individual patient risk fac-
tors when prescribing.
For patients with T2D who are at particularly high risk 
for CV events, the CV risks and benefits of antidiabetic 
drugs should inform prescribing decisions. Currently, 
only empagliflozin and liraglutide are licenced for use in 
patients with T2D and CVD, and these therapies should be 
prioritized when considering treatment for patients with 
comorbid CVD.
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